Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04610892 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 423
- Enrollment target
NCT04610892 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 423 participants.
The verdict
NCT04610892, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 423 participants
- Enrollment target
Study Summary
A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MEDI6570
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2020-11-04 |
| Est. Completion | 2023-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04610892
The ClinicalTrials.gov registry entry for NCT04610892 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 423 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04610892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04610892 about?
NCT04610892 is a clinical study titled "Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction". A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.
What is the current status of trial NCT04610892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 423 participants. The study started on 2020-11-04. Estimated completion is 2023-11-08.
What interventions are being tested in trial NCT04610892?
The interventions under investigation include: Placebo (BIOLOGICAL), MEDI6570 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04610892?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.